BioLife Solutions (BLFS) 10% owner Casdin Partners Master Fund sold 1,200,000 shares for $28.1M at an average $23.44
Insider transactions reported
Casdin Partners Master Fund, L.P. (10% owner at BioLife Solutions Inc., BLFS) reported that they sold 1,200,000 shares for $28.1M at an average $23.44 between May 19, 2026 and May 21, 2026. After these transactions the filing shows 4,757,165 shares held indirectly (See footnote).
- Reporting person
- Casdin Partners Master Fund, L.P.
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| May 19, 2026 | Open-market sale (S) | Common Stock, par value $0.001 per share1 | -300,000 | $22.65 | $6.8M | 5,657,165 indirect |
| May 20, 2026 | Open-market sale (S) | Common Stock, par value $0.001 per share1 | -250,000 | $23.70 | $5.93M | 5,407,165 indirect |
| May 21, 2026 | Open-market sale (S) | Common Stock, par value $0.001 per share1 | -650,000 | $23.70 | $15.4M | 4,757,165 indirect |
Holdings before and after
- Common Stock, par value $0.001 per share: 5,957,165 to 4,757,165 indirect, See footnote
Footnotes from the filing
- 1. The securities are owned directly by Casdin Partners Master Fund, L.P. (the Master Fund ) and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ( Casdin Capital ), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC ( Casdin GP ), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin Capital and Casdin GP.
Transaction codes in this filing
- Open-market sale:
- Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
FAQ
What did Casdin Partners Master Fund report in this BLFS Form 4?
Casdin Partners Master Fund, L.P. (10% owner at BioLife Solutions Inc., BLFS) reported that they sold 1,200,000 shares for $28.1M at an average $23.44 between May 19, 2026 and May 21, 2026. After these transactions the filing shows 4,757,165 shares held indirectly (See footnote).
How many BLFS shares does Casdin Partners Master Fund hold after this filing?
The filing shows 4,757,165 shares held indirectly (See footnote) after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
Was this BLFS insider sale made under a 10b5-1 plan?
The filing's footnotes do not mention a Rule 10b5-1 trading plan.
What does transaction code S mean on an SEC Form 4?
Code S marks a sale in the open market or a private deal. The insider received cash for these securities.
Historical context for BLFS
Across the 11 sessions after earlier BLFS headlines, the stock closed higher 4 times and lower 7 times, with a median move of 1.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BLFS | SPY |
|---|---|---|---|
| May 8, 2026 | BioLife Solutions Reports First Quarter 2026 Financial Results | -4.7% | +0.8% |
| Apr 24, 2026 | BioLife Solutions to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026 | -1.6% | +0.8% |
| Apr 22, 2026 | BioLife Solutions Wins INTERPHEX 2026 Biotech Innovation Award for CellSeal® CryoCase | +1.9% | +1.0% |
| Feb 27, 2026 | BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations | +7.7% | -0.5% |
| Feb 17, 2026 | BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026 | +0.6% | +0.2% |
| Feb 12, 2026 | BioLife Solutions Signs Multi-Year Supply Agreement with Qkine Limited to Expand its Product Portfolio into the Rapidly Growing Cytokines Market | -3.0% | -1.5% |
Earlier insider filings at BLFS
- Apr 10, 2026SEC Form 4 filed by Mathew Aby J.
- Apr 10, 2026SEC Form 4 filed by Berard Todd
- Apr 10, 2026SEC Form 4 filed by Wichterman Troy
- Mar 31, 2026SEC Form 4 filed by Foster Karen A.
- Mar 23, 2026SEC Form 4 filed by De Greef Roderick
Keep researching BLFS
- BLFS insider tradesEvery buy and sale reported by BioLife Solutions Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- BLFS earnings historyPast BioLife Solutions Inc. earnings releases, newest first.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
Follow BLFS and get a push notification the moment its next story breaks.